홈 » 브리티시컬럼비아 소개 » 대만

브리티시컬럼비아와 대만

대만은 지리적 위치로 인해 동아시아와 동남아시아에 대한 접근성과 유통이 용이하여 광범위한 아시아 시장에 새로 진출하는 기업이 지역 허브로 삼을 가능성이 높습니다. 대만은 글로벌 기술 공급망의 핵심 허브이며, 매우 혁신적이고, 특허 출원 분야에서 1위를 차지했습니다. 또 대만은 인프라가 우수하고 고학력 인력을 보유하고 있으며 국제 무역에 매우 개방적입니다.

무역 및 투자 하이라이트

대만과 캐나다는 공급망 회복력, 상업적 기회를 촉진하고 과학, 기술, 혁신, 교육, 친환경 경제에 대한 협력을 증진하기 위한 논의를 진행하고 있습니다.
대만은 향후 더 많은 무역 협정에 참여하여 더 많은 시장과 거래 기회를 창출할 계획입니다.
캐나다는 인도-태평양 전략을 통해 기존 파트너인 호주, 뉴질랜드, 대만 및 참여 경제권 원주민과 협력하여 원주민 경제 및 무역 협력 협정(IPETCA)을 이행함으로써 원주민의 경제권 강화를 지원할 계획입니다.

대만 한눈에 보기

통화 단위는 USD로 표시됩니다.

외국인 투자자 및 B.C. 수출업체를 위한 기회

농식품 및 해산물

Taiwan imports most of its food supply. The import of seafood products has grown substantially in recent years, creating significant opportunities for B.C.’s high-quality Agrifood and Seafood products in Taiwan. Vegetarian food and plant-based protein products are likely to find success in Taiwan due to the high rate of vegetarianism in the population.

청정기술 및 청정에너지

B.C.’s advantages in cleantech research pairs naturally with Taiwan’s expertise in high-tech manufacturing, to help transform designs and concepts into tangible, marketable products. As Taiwan phases out its nuclear power program and decreases oil and coal consumption, the demand for LNG and renewable energy will grow significantly. B.C. is well-positioned to be a valuable partner to Taiwan, as it transitions its energy supply both through LNG exports and the clean energy technologies over the longer term. Hydrogen fuel cell technology, as a renewable source of energy, is also highly attractive as Taiwan attempts to meet 2050 emissions targets.

ICT

Taiwan is a major international player for semi-conductors and integrated circuits. Government policies prioritize innovation and developing the tech sector. There are many opportunities to be found in segments involving the Internet of Things (IOT), Artificial Intelligence (AI), ICT, agritech, online gaming, fintech, digital health, smart manufacturing, and smart transportation.

생명과학

Taiwan has been investing in its biotech sector since the 1980s. In 2021, the government amended the Development of Biotech and New Pharmaceutical Industry Act with the aim of generating opportunities in the biotechnology sector by attracting greater investment.

Taiwan’s pharmaceutical companies act mostly as Contract Development & Manufacturing Organizations (CDMO) and are historically strong in the generic drugs development and manufacturing.

Areas that present significant opportunities for B.C. firms include pharmaceutical products, medical devices and instruments, and health services, such as conducting clinical trials, licencing new intellectual property, and regulatory approval consultancy.